The pharmacologist

Ana Belén Elgoyhen, Carla Vanina Rothlin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Keypoints: 1. One in 10 adults has subjective tinnitus, and for 1 in 100 adults, tinnitus severely affects their quality of life. 2. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the market. 3. Since in some individuals, tinnitus causes irritability, agitation, stress, depression, insomnia, and interferes with normal life, even a drug that produces a small but significant effect would have a huge therapeutic impact. 4. A glimpse of hope is appearing in the near future, as some pharmaceutical industries now have compounds targeting tinnitus in their pipeline. 5. If these compounds finally reach the market, they will set a new era that will revolutionize the treatment of tinnitus.

Original languageEnglish (US)
Title of host publicationTextbook of Tinnitus
PublisherSpringer New York
Pages251-257
Number of pages7
ISBN (Print)9781607611448
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Tinnitus
Hope
Drug Industry
Sleep Initiation and Maintenance Disorders
Drug Delivery Systems
Pharmaceutical Preparations
Quality of Life
Depression
Therapeutics

Keywords

  • Animal models
  • Drug discovery
  • Lead compounds
  • Phantom sound
  • Tinnitus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Elgoyhen, A. B., & Rothlin, C. V. (2011). The pharmacologist. In Textbook of Tinnitus (pp. 251-257). Springer New York. https://doi.org/10.1007/978-1-60761-145-5_30

The pharmacologist. / Elgoyhen, Ana Belén; Rothlin, Carla Vanina.

Textbook of Tinnitus. Springer New York, 2011. p. 251-257.

Research output: Chapter in Book/Report/Conference proceedingChapter

Elgoyhen, AB & Rothlin, CV 2011, The pharmacologist. in Textbook of Tinnitus. Springer New York, pp. 251-257. https://doi.org/10.1007/978-1-60761-145-5_30
Elgoyhen AB, Rothlin CV. The pharmacologist. In Textbook of Tinnitus. Springer New York. 2011. p. 251-257 https://doi.org/10.1007/978-1-60761-145-5_30
Elgoyhen, Ana Belén ; Rothlin, Carla Vanina. / The pharmacologist. Textbook of Tinnitus. Springer New York, 2011. pp. 251-257
@inbook{6cad87d2037f4cf3b806eec1f9635ffa,
title = "The pharmacologist",
abstract = "Keypoints: 1. One in 10 adults has subjective tinnitus, and for 1 in 100 adults, tinnitus severely affects their quality of life. 2. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the market. 3. Since in some individuals, tinnitus causes irritability, agitation, stress, depression, insomnia, and interferes with normal life, even a drug that produces a small but significant effect would have a huge therapeutic impact. 4. A glimpse of hope is appearing in the near future, as some pharmaceutical industries now have compounds targeting tinnitus in their pipeline. 5. If these compounds finally reach the market, they will set a new era that will revolutionize the treatment of tinnitus.",
keywords = "Animal models, Drug discovery, Lead compounds, Phantom sound, Tinnitus",
author = "Elgoyhen, {Ana Bel{\'e}n} and Rothlin, {Carla Vanina}",
year = "2011",
doi = "10.1007/978-1-60761-145-5_30",
language = "English (US)",
isbn = "9781607611448",
pages = "251--257",
booktitle = "Textbook of Tinnitus",
publisher = "Springer New York",

}

TY - CHAP

T1 - The pharmacologist

AU - Elgoyhen, Ana Belén

AU - Rothlin, Carla Vanina

PY - 2011

Y1 - 2011

N2 - Keypoints: 1. One in 10 adults has subjective tinnitus, and for 1 in 100 adults, tinnitus severely affects their quality of life. 2. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the market. 3. Since in some individuals, tinnitus causes irritability, agitation, stress, depression, insomnia, and interferes with normal life, even a drug that produces a small but significant effect would have a huge therapeutic impact. 4. A glimpse of hope is appearing in the near future, as some pharmaceutical industries now have compounds targeting tinnitus in their pipeline. 5. If these compounds finally reach the market, they will set a new era that will revolutionize the treatment of tinnitus.

AB - Keypoints: 1. One in 10 adults has subjective tinnitus, and for 1 in 100 adults, tinnitus severely affects their quality of life. 2. Despite the significant unmet clinical need for a safe and effective drug targeting tinnitus relief, there is currently not a single FDA-approved drug on the market. 3. Since in some individuals, tinnitus causes irritability, agitation, stress, depression, insomnia, and interferes with normal life, even a drug that produces a small but significant effect would have a huge therapeutic impact. 4. A glimpse of hope is appearing in the near future, as some pharmaceutical industries now have compounds targeting tinnitus in their pipeline. 5. If these compounds finally reach the market, they will set a new era that will revolutionize the treatment of tinnitus.

KW - Animal models

KW - Drug discovery

KW - Lead compounds

KW - Phantom sound

KW - Tinnitus

UR - http://www.scopus.com/inward/record.url?scp=84887945170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887945170&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-145-5_30

DO - 10.1007/978-1-60761-145-5_30

M3 - Chapter

SN - 9781607611448

SP - 251

EP - 257

BT - Textbook of Tinnitus

PB - Springer New York

ER -